期刊
LEUKEMIA
卷 35, 期 7, 页码 1864-1872出版社
SPRINGERNATURE
DOI: 10.1038/s41375-021-01257-7
关键词
-
资金
- Hairy Cell Foundation
Experts recommend using targeted and non-immunosuppressive agents as first-line treatment for classic Hairy Cell Leukemia, while also emphasizing the importance of active surveillance for patients and preventive measures against COVID-19.
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据